Among adults with chronic spontaneous urticaria inadequately controlled by H1 antihistamine treatment, remibrutinib improved ...

If you're being treated for hives, your physician will want to hear what you think about your treatment. Is it working? Are your symptoms improving, staying the same, or getting worse? You may be ...

A panel of experts discuss the clinical trials of dupilumab, the resultant data, and the response of the FDA when approval was requested. Dupilumab has been evaluated in phase 3 clinical trials in ...

Washington, DC, Oct. 01, 2025 (GLOBE NEWSWIRE) -- On this Urticaria Day (UDAY), the Asthma and Allergy Foundation of America (AAFA), We CU, and The Mast Cell Disease Society (TMS) aim to raise ...

The FDA has approved Quzyttir for the treatment of acute urticaria in adults and children 6 months of age and older. The Food and Drug Administration (FDA) has approved Quzyttir (cetirizine ...

In this discussion, panelists explore the potential role of new Bruton tyrosine kinase inhibitors in the treatment landscape for chronic spontaneous urticaria (CSU), evaluating their stages of ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

The approval marks the first for a targeted treatment in chronic spontaneous urticaria in Europe in over a decade.

Patients with chronic spontaneous urticaria who respond rapidly to omalizumab show longer treatment persistence and require ...

Women with CSU experience a greater burden of disease than men, with greater predominance and worsening burden observed in midlife.